ReviewMycopathologia2018
Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis.
Review in Mycopathologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 61 citations in OpenAlex.
- Inhalation of N-Chlorotaurine Is an Effective Treatment of <italic>Aspergillus fumigatus</italic> Pneumonia in Mice.Journal of innate immunity · 2026Article
- Article
- Influence of Fungal Colonization on Exacerbations in Patients with Cystic Fibrosis.Journal of fungi (Basel, Switzerland) · 2024Article
- Metagenomics Applied to the Respiratory Mycobiome in Cystic Fibrosis.Mycopathologia · 2024Review
- Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections.Clinical microbiology reviews · 2024Review
- The clinical yield of bronchoscopy in the management of cystic fibrosis: A retrospective multicenter study.Pediatric pulmonology · 2023Article
- Dot Immunobinding Assay for the Rapid Serodetection ofJournal of fungi (Basel, Switzerland) · 2023Article
- The convoluted process of diagnosing pulmonary mycosis caused by Exophiala dermatitidis: a case report.BMC infectious diseases · 2022Article
- Pseudomonas Synergizes with Fluconazole againstInfection and immunity · 2022Article
- Metrics of Antifungal Effects of Ciprofloxacin onJournal of fungi (Basel, Switzerland) · 2022Article
- Emerging Fungal Threats in Cystic Fibrosis.Mycopathologia · 2021Review
- The Host Immune Response toJournal of fungi (Basel, Switzerland) · 2021Review
- Microbial Community Composition in Explanted Cystic Fibrosis and Control Donor Lungs.Frontiers in cellular and infection microbiology · 2021Article
- Managing Fungal Infections in Cystic Fibrosis Patients: Challenges in Clinical Practice.Infection and drug resistance · 2021Review
- Update on Respiratory Fungal Infections in Cystic Fibrosis Lung Disease and after Lung Transplantation.Journal of fungi (Basel, Switzerland) · 2020Review
- Risk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function.Scientific reports · 2020Article
- Evaluation of a New Culture Protocol for Enhancing Fungal Detection Rates in Respiratory Samples of Cystic Fibrosis Patients.Journal of fungi (Basel, Switzerland) · 2020Article
- Review
- Human inborn errors of immunity to infection affecting cells other than leukocytes: from the immune system to the whole organism.Current opinion in immunology · 2019Review
- Coexistence of Candida species and bacteria in patients with cystic fibrosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic fibrosis (CF) is a chronic lethal multi-system condition; however, most of the morbidity and mortality is dependent on the status of the respiratory system. Progressive respiratory decline is mediated by chronic infection and inflammation, punctuated by important acute events known as pulmonary exacerbations which can lead to accelerated decline. The main bacterial species causing infections include Pseudomonas aeruginosa, Staphylococcus aureus, Haemophilus influenzae and Achromobacter xylosoxidans. In addition to bacteria, fungi are detected in a significant number of patients. The impact of fungal colonization of the airways is still not completely elucidated, but an increasing body of evidence suggests an important role for moulds and yeasts. Although fungal infections are rare, fungi can cause severe pneumonia requiring appropriate targeted treatment. The most common fungi in respiratory samples of patients with CF are Aspergillus fumigatus, Aspergillus terreus and Scedosporium species for filamentous fungi, and yeasts such as Candida albicans and Candida glabrata. Therapeutic strategies depend on the detected fungus and the underlying clinical status of the patient. The antifungal therapy can range from a simple monotherapy up to a combination of three different drugs. Treatment course may be indicated in some patients for two weeks and in others for up to six months, and in rare cases even longer. New antifungal drugs have been developed and are being tested in clinical studies offering the hope of therapeutic alternatives to existing drugs. Identifying relevant risk factors and diagnostic criteria for fungal colonization and infection is crucial to enabling an adequate prevention, diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.